NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate30-09-2021
30-09-2021
Natco Pharma Ltd - 524816 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results along with scrutinizer''s Report30-09-2021
Natco Pharma Ltd - 524816 - Closure of Trading Window
Intimation of Trading Window closure for the quarter ended September 30, 202130-09-2021
NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome and Proceedings of 38th Annual General Meeting30-09-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of 38th AGM notice publication03-09-2021
NATCO PHARMA LTD. - 524816 - Book Closure
Book closure for the purpose of AGM and E-voting02-09-2021
NATCO PHARMA LTD. - 524816 - Reg. 34 (1) Annual Report
Annual Report for the year 2020-2102-09-2021
Natco Pharma arm launches Lenalidomide in Canada
This drug is used in combination with dexamethasone for the treatment of multiple myeloma in patients02-09-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco Pharma (Canada) Inc. announces the launch of Pr NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid(r)02-09-2021
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates31-08-2021